ArticleOncotarget2016
Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
Brian P Danysh et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
50 papers cite it
this papertrialcites it